Who
Jane A. Gross
Director
Company insider
Files Form 4 as: Director, aTyr Pharma; SVP & Chief Scientific Officer, Aptevo Therapeutics.
In numbers
- Trades disclosed
- 54
- Buys
- 1
- Sells
- 0
- Bought
- $15K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 3 Feb 2017
- Last trade
- 11 May 2026
- Last filed
- 13 May 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Mar 2025filed 17 Mar 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $15K3,750 at $4.00 | filing |
| 22 May 2024filed 23 May 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 26 Apr 2023filed 28 Apr 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 26 Apr 2023filed 28 Apr 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —6,000 | filing |
| 26 Apr 2022filed 28 Apr 2022 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 28 Apr 2021filed 29 Apr 2021 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,428 at $0.00 | filing |
| 29 Jan 2021filed 17 Feb 2021 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 29 Jan 2021filed 17 Feb 2021 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,072 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,779 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,908 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,407 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,407 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,814 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,814 | filing |
| 27 Jul 2020filed 29 Jul 2020 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,784 | filing |
News
No headline names them, or the companies they trade most, lately.